AusperBio secures $120 million Series C to push hepatitis B antisense therapy into Phase 3
AusperBio Therapeutics announced it has closed a $120 million Series C financing round aimed at moving its hepatitis B antisense oligonucleotide candidate toward late‑stage trials and eventual market launch.
The funding, led by RA Capital Management with participation from existing backers such as HanKang Capital and Qiming Venture Partners, adds to earlier rounds that have raised over $300 million since the company’s 2019 founding.
The lead program, identified as AHB‑137, is an unconjugated antisense oligonucleotide that targets viral protein production and DNA replication, and is currently being evaluated in a late‑stage study in China.
CEO Guofeng Cheng said the capital infusion marks a pivotal moment for the firm as it seeks a functional cure for chronic hepatitis B and plans to expand its oligonucleotide platform.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that